2 Must-Buy Medical Stocks With Strong Momentum
Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is DaVita (DVA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Stocks Trading Near 52-Week High With More Upside Potential
Investors target stocks that have lately been on a bull run. Stocks like PPC, THC, DVA and UHS are seeing price strength and have a high chance of carrying the momentum forward.
DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run?
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DaVita HealthCare (DVA) Is Up 0.56% in One Week: What You Should Know
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is DaVita (DVA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging DaVita (DVA) This Year?
Here is how DaVita HealthCare (DVA) and Avadel (AVDL) have performed compared to their sector so far this year.
DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up
DaVita's (DVA) robust segmental revenues drive its second-quarter performance.
DaVita HealthCare (DVA) Q2 Earnings and Revenues Surpass Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.08 per share a year ago.
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, DaVita HealthCare (DVA) closed at $136.47, marking a -1.93% move from the previous day.
